Analyzing Lazard (NYSE:LAZ) & MDB Capital (NASDAQ:MDBH)

Lazard (NYSE:LAZ) and MDB Capital (NASDAQ:MDBH) are both finance companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Earnings and Valuation

This table compares Lazard and MDB Capital”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lazard	$3.10 billion	1.53	$236.83 million	$2.53	16.76
MDB Capital	$4.91 million	6.00	-$21.25 million	($2.12)	-1.35

Lazard has higher revenue and earnings than MDB Capital. MDB Capital is trading at a lower price-to-earnings ratio than Lazard, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Lazard has a beta of 1.41, indicating that its stock price is 41% more volatile than the S&P 500. Comparatively, MDB Capital has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Lazard and MDB Capital, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lazard	3	5	4	0	2.08
MDB Capital	1	0	0	0	1.00

Lazard currently has a consensus price target of $52.00, indicating a potential upside of 22.64%. Given Lazard’s stronger consensus rating and higher probable upside, analysts clearly believe Lazard is more favorable than MDB Capital.

Profitability

This table compares Lazard and MDB Capital’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lazard	8.47%	29.30%	5.52%
MDB Capital	N/A	-35.92%	-34.75%

Insider & Institutional Ownership

54.8% of Lazard shares are held by institutional investors. Comparatively, 0.4% of MDB Capital shares are held by institutional investors. 1.0% of Lazard shares are held by insiders. Comparatively, 55.8% of MDB Capital shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Lazard beats MDB Capital on 12 of the 14 factors compared between the two stocks.

About Lazard

Lazard, Inc., together with its subsidiaries, operates as a financial advisory and asset management firm in North and South America, Europe, the Middle East, Asia, and Australia. It operates in two segments, Financial Advisory and Asset Management. The Financial Advisory segment offers financial advisory services, such as mergers and acquisitions, capital markets, shareholder, sovereign, geopolitical advisory, and other strategic advisory services, as well as restructuring and liability management, and capital raising and placement services. This segment offers its services to corporate, partnership, institutional, government, sovereign, and individual clients to various industry areas, including consumers, financial institutions, healthcare and life sciences, industrials, power and energy/infrastructure, real estate, technology, telecommunication, and media and entertainment. The Asset Management segment offers a range of investment solutions; investment and wealth management services in equity and fixed income strategies; asset allocation strategies; and alternative investments and private equity funds to corporations, public funds, sovereign entities, endowments and foundations, labor funds, financial intermediaries, and private clients. Lazard, Inc. was incorporated in 1848 and is headquartered in New York, New York.

About MDB Capital

MDB Capital Holdings, LLC, through its subsidiaries, primarily operates as a broker-dealer. The company operates through two segments, Broker Dealer & Intellectual Property Service, and Technology Development. The Broker Dealer & Intellectual Property Service segment operates as a full-service broker dealer that focuses on conducting private and public securities offerings, as well as providing research services for investment banking due diligence. The Technology Development segment engages in the synthetic biology technology development business. The company was founded in 1997 and is based in Addison, Texas.